Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
Go back to Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension| INSMED (NASDAQ: INSM) | Delayed: 123.98 +1.40 (1.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $122.58 | 52 Week High | $19.30 | |||
| Open | $124.16 | 52 Week Low | $9.02 | |||
| Day High | $127.40 | P/E | N/A | |||
| Day Low | $122.88 | EPS | $-1.69 | |||
| Volume | 1,592,241 | |||||
